Pure Global AI
NCT06301295Not yet recruiting

Feasibility of Targeted Bronchial Washing Fluid for Molecular Testing With Next Generation Sequencing in Patients Suspicious of Early-stage Lung Cancer

Pusan National University HospitalClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Lung Cancer
Drug/Device/Intervention
Ultarthin bronchoscopy with intratumoral washing
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Pusan National University Hospital
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2024
End date
Dec 31, 2026
Enrollment
50 participants
Primary outcome

Genetic alteration with Next Generation Sequencing detection rate in intratumoral washing fluid

Summary

This is a single center, clinical trial evaluating the relevance of intratumoral washing for
 detection of generic alteration with Next Generation Sequencing.

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm of bronchus and lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm: Overlapping lesion of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06301295
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06301295 through Pure Global AI's free database. This phase not specified trial is sponsored by Pusan National University Hospital and is currently Not yet recruiting. The study focuses on Lung Cancer. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.